- Sorrento Therapeutics Inc (NASDAQ:SRNE) has entered into an option agreement with The Texas A&M University System for exclusive rights to highly potent main protease (MPro) inhibitors against SARS-CoV-2.
- This latest agreement bolsters Sorrento’s portfolio of preclinical and clinical therapeutic candidates targeting COVID-19.
- Under the agreement terms, Sorrento has an exclusive option to license patents covering the MPro inhibitor drug candidates exclusively.
- The MPro inhibitors have demonstrated strong cellular antiviral potency against SARS-CoV-2 in preclinical studies.
- Several MPro inhibitors were identified that exhibited antiviral effects against diverse SARS-CoV-2 variants.
- Sorrento may exercise its right to enter into a worldwide exclusive license agreement at any time during the option period.
- Price Action: SRNE shares are up 0.32% at $8.96 during the market session on the last check Tuesday.
Oncolytics Biotech Announces Publication Of Preclinical Data Demonstrating The Synergistic Anti-Cancer Activity Of Pelareorep Combined With CAR T Cell Therapy In Solid Tumors In Science Translational Medicine
- Pelareorep-CAR T combination may expand the commercial potential of CAR T cells to solid tumors
- Combining CAR T cells with pelareorep prevented antigen escape by creating CAR T cells with dual specificity through a
